Duration of treatment with 5-aminosalicylic acid compounds.
The development of 5-aminosalicylic acid (5-ASA) therapy as a life long treatment for ulcerative colitis is reviewed from its origins in the 1940s to the present day. The drug was designed to treat rheumatoid arthritis, but was found helpful in the management of nine patients with ulcerative colitis. This discovery preceded the emergence of the clinical trial as a tool for assessing a new drug's efficacy; as a result it lacked scientific rigour and was selective in its presentation of results. Nevertheless it identified the future cornerstone of therapy in ulcerative colitis. In 1962, the first double blind controlled trial of sulphasalazine was conducted on 40 patients. Outcome measures were subjective and included symptoms and an assessment of the rectal mucosa. In 1973, the first two papers on the role of sulphasalazine in maintenance of remission were published. Both used placebo controls and had a stratified design. Outcomes were measured using "an intention to treat" approach. The British study of 64 patients used both subjective and objective criteria to assess outcomes. Patients on placebo had a relapse rate four times patients on active treatment and this founded the basis for a life long approach to therapy with 5-ASA compounds in ulcerative colitis. However, in 1985, a small "on demand" study of 32 patients suggested this approach might be as effective as continuous treatment. Some support for this view came from an Italian study which showed no benefit to continued treatment for those in remission for two years or more. The central problem these studies identify is that of adherence to treatment in the long-term. Few studies have considered patients' attitudes to continuous therapy and it is an area that needs further investigation.
Moshkovska
T
T
Leicester General Hospital, University Hospitals of Leicester NHS Trust, Gwendolen Road, Leicester LE5 4PW, United Kingdom.
Mayberry
J-F
JF
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000266:history / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000266:history; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D049673:History, 20th Century; D006801:Humans; D019804:Mesalamine / Q000266:history / Q000627:therapeutic use*; D055502:Secondary Prevention; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine
BMJ. 1992 Jul 4;305(6844):20-2
1638191
Aliment Pharmacol Ther. 2004 Jun 1;19(11):1147-52
15153167
Gastroenterology. 1994 Jul;107(1):117-20
7912678
Dis Colon Rectum. 1985 Dec;28(12):929-30
2866071
Lancet. 1962 May 26;1(7239):1094-6
13865153
Am J Gastroenterol. 2003 Jul;98(7):1535-44
12873575
Scand J Gastroenterol. 1973;8(1):71-4
4144533
Lancet. 1978 Nov 4;2(8097):955-7
81986
Aliment Pharmacol Ther. 2004 Mar 1;19(5):529-35
14987321
Br Med J (Clin Res Ed). 1987 Mar 14;294(6573):683-4
3105688
Am J Gastroenterol. 2001 Oct;96(10):2929-33
11693328
Gut. 2004 Sep;53 Suppl 5:V1-16
15306569
Aliment Pharmacol Ther. 2000 Feb;14(2):145-53
10651654
Am J Gastroenterol. 1995 Mar;90(3):381-7
7872274
JAMA. 1994 Jan 5;271(1):59-63
8258890
Gut. 1973 Dec;14(12):923-6
4150435
Cochrane Database Syst Rev. 2002;(4):CD000544
12519547
Eur J Gastroenterol Hepatol. 1996 Dec;8(12):1179-83
8980937
Ital J Gastroenterol. 1994 Sep;26(7):334-7
7812025
Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1275-80
14624149
Aliment Pharmacol Ther. 1999 Mar;13(3):373-9
10102971
Gut. 1964 Oct;5:437-42
14218553